Clinical Evaluation Specialist for Active Implantable Medical Devices

A clinical evaluation specialist assesses whether the available clinical evidence adequately demonstrates the safety, performance, and benefit-risk profile of an active implantable medical device. This includes literature review, evidence appraisal, CER authoring or review, PMCF assessment, alignment with risk management, and ensuring the clinical narrative is consistent with technical documentation and the target regulatory pathway.

Active implantable medical devices are high-risk products, so regulators expect a deeper and more methodical clinical justification than for lower-risk devices. Clinical evaluation must address long-term safety, device performance, residual risks, intended use, and post-market evidence. Weak clinical documentation can trigger major deficiencies, delay approvals, or undermine the credibility of the entire submission package.

For markets such as the EU, a CER is a core part of the technical documentation and is especially critical for implantable devices. Even outside the EU, manufacturers still need a structured clinical evidence rationale to support submissions, approvals, and post-market obligations. The exact format varies by market, but a documented clinical evaluation is generally essential for high-risk implantables.

Yes. Elexes evaluates whether existing literature, prior clinical data, PMCF outputs, and real-world evidence are sufficient for your target submission. For active implantable devices, equivalence arguments are often limited and evidence expectations are higher, so we assess whether additional clinical investigation data is likely needed and build a practical evidence strategy around that determination.

We review the clinical evaluation alongside the ISO 14971 risk management file to ensure hazards, residual risks, benefit-risk conclusions, and clinical claims are consistent. For active implantable devices, this alignment is critical because reviewers often compare CER conclusions against risk analyses, PMS outputs, and labeling. Any mismatch can create avoidable questions during submission or audit review.

Yes. Elexes reviews PMCF plans and reports to determine whether they are proportionate, scientifically justified, and suitable for the device's risk profile and market obligations. For active implantable devices, PMCF is often a major expectation because long-term safety and performance data are central to ongoing compliance. We also help strengthen PMCF strategy where current activities are insufficient.

Elexes supports manufacturers across major regulatory frameworks including FDA, EU MDR, TGA, Health Canada, and other international pathways. Our team helps adapt clinical evidence strategy and documentation to the expectations of each market, whether the need is CER development, submission readiness, deficiency response, or broader technical documentation alignment for implantable device programs.

A submission readiness assessment identifies weaknesses before regulators do. Elexes reviews clinical evidence adequacy, documentation completeness, traceability, risk alignment, and submission consistency against the actual pathway you plan to use. For active implantable devices, this early review can prevent deficiency cycles, reduce rework, and give your team a prioritized action plan for a more defensible submission.